Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How do you treat a Trulicity® (dulaglutide) overdose?

In the event of overdose, appropriate supportive care should be initiated according to the patient’s clinical signs and symptoms.

Detailed Information

Overdoses of dulaglutide have been reported in clinical studies.1

Effects of overdose with dulaglutide in clinical studies have included GI disorders and non-severe hypoglycemia.1

In the event of an overdose, appropriate supportive treatment such as frequent plasma glucose monitoring, should be initiated according to the patient’s clinical signs and symptoms.1

Enclosed Prescribing Information

TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly

Reference

1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

GI = gastrointestinal

Date of Last Review: July 07, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical